MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma
MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma
复制标题
DOI：
10.1007/s13277-013-0685-3
复制
发表时间：
2013-06-01
期刊：
影响因子：
--
通讯作者：
Jiang, Xiao-Xiao
中科院分区：
文献类型：
--
作者：
Chen, Da-Wei;Fan, Yao-Fu;Jiang, Xiao-Xiao
本研究旨在检测MTA 2在胰腺导管腺癌（PDA）中的表达，并分析其与PDA患者预后的关系。应用实时定量逆转录聚合酶链反应（RT-PCR）和免疫组化方法检测PDA患者原发癌组织及癌旁组织中MTA 2 mRNA和蛋白的表达。我们发现，MTA 2 mRNA和蛋白表达水平均显着上调PDA病变与相邻的非癌组织相比。免疫组化结果显示，MTA 2高表达与肿瘤分化程度低、TNM分期、淋巴结转移有关。Kaplan-Meier生存分析显示，MTA 2高表达患者的总生存率低于低表达患者。多因素分析显示，MTA 2蛋白高表达是PDA患者的独立预后因素。提示MTA 2的过度表达可能在PDA的发生发展中起重要作用，MTA 2的表达可作为PDA预后不良的生物标志物。
The aim of this study was to detect MTA2 expression in pancreatic ductal adenocarcinoma (PDA) and to analyze its association with prognosis of PDA patients. MTA2 mRNA and protein expression were determined by real-time quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry in specimens of primary cancer and their adjacent noncancerous tissues in PDA patients. We found that MTA2 mRNA and protein expression levels were both significantly upregulated in PDA lesions compared with adjacent noncancerous tissues. Immunohistochemistry showed that high MTA2 expression was correlated with poor tumor differentiation, TNM stage, and lymph node metastasis. Kaplan-Meier survival analysis showed that patients with high expression levels of MTA2 showed lower overall survival rate than those with low expression levels. Multivariate analysis showed that high MTA2 protein expression was an independent prognostic factor for PDA patients. Our study suggests that overexpression of MTA2 may play an important role in the progression of PDA and MTA2 expression may serve as a biomarker for poor prognosis for PDA.